A new study published by researchers from the University of Texas MD Anderson Cancer Center, the Karolinska Institutet, and Moffitt Cancer Center has identified an unexpected mechanism underlying resistance to cancer immunotherapy: cancer-induced damage to adjacent nerves. This discovery could reshape how oncologists approach treatment for patients who do not respond to checkpoint inhibitors and other immunotherapies.
The research, which involved collaborative analysis of tumor samples and preclinical models, found that tumors can actively disrupt nerve fibers in their microenvironment. This neural damage appears to suppress local immune responses, essentially allowing the cancer to evade the immune system despite the presence of immunotherapy drugs. The findings suggest that protecting or repairing these nerves could enhance the effectiveness of existing treatments.
Immunotherapy has revolutionized cancer care, but many patients either do not respond or develop resistance over time. Until now, resistance mechanisms have largely focused on tumor genetics, immune cell exhaustion, and the tumor microenvironment. This study adds a new dimension by highlighting the role of the peripheral nervous system in modulating anti-tumor immunity.
The teams demonstrated that when nerves are damaged by tumor growth, they release factors that attract immunosuppressive cells and dampen the activity of cytotoxic T cells—the key soldiers of the immune response. In animal models, preventing nerve damage or promoting nerve regeneration restored sensitivity to immunotherapy.
While the research is still in its early stages, it opens up potential therapeutic strategies. Drugs that protect nerves or promote neural repair, combined with immunotherapy, could be tested in clinical trials. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are already exploring innovative approaches in cancer immunotherapy, and this new insight could complement their efforts.
The study underscores the importance of interdisciplinary collaboration in cancer research. By connecting oncology with neuroscience, the researchers have uncovered a previously overlooked aspect of tumor biology. Further studies will be needed to translate these findings into clinical applications, but the implications are significant for patients who currently have limited options after immunotherapy fails.
For more information on the research, readers can refer to the original publication. The study was supported by grants from the National Institutes of Health and other funding agencies.
